Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Multi-cancer screening draws investment as clinical hurdles remain, Sciety says

By Public Technologies
  • Multi-cancer early detection faces clinical validation hurdles despite growing investment, according to an industry analysis published Nov. 3, 2026.
  • GRAIL’s NHS-Galleri trial, involving over 142,000 participants, failed to show a statistically significant reduction in stage III and IV cancer diagnoses.
  • Samsung invested USD 110 million in GRAIL in 2026; Freenome raised over USD 300 million through its IPO for blood-based cancer diagnostics.
  • Abbott acquired Exact Sciences in a deal valuing the cancer diagnostics company at about USD 21 billion.
  • The National Cancer Institute’s Vanguard study will assess testing and diagnostic follow-up in up to 24,000 participants, informing a larger randomized trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sciety AB published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.